BARD1 and neoplasm: While germline loss-of-function variants have been reported across several tumor types, with over 4000 identified in the National Center for Biotechnology Information ClinVar database [62,63,64], most BARD1 variants are classified as either “benign” or of “uncertain significance” due to limited clinical and functional data [46,47,65,66,67,68,69,70,71,72,73].